Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

2

Other

1

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Cyclin-dependent kinase 4

2

Cyclin-dependent kinase 6

2

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

2

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

2017

2

Unknown

1

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Breast cancer

2

Glioblastoma

2

HER2-negative advanced breast cancer

2

Melanoma

2

Non-small cell lung cancer

2

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

2

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Penetrant

2

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Eli Lilly

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

3

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

3

EPA CompTox

3

FDA UNII

3

PUBCHEM

3

DRUG BANK

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTINEOPLASTIC AGENTS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

OTHER ANTINEOPLASTIC AGENTS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Protein kinase inhibitors

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

2

Salts, Hydrates, Esters, etc.

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 3 of 3 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

ABEMACICLIB

60UAB198HK

Export Data
Search for Structure

Status:

US Approved Rx (2017)

First approved in 2017

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Cyclin-dependent kinase 6

Cyclin-dependent kinase 4

Conditions:

Non-small cell lung cancer

HER2-negative advanced breast cancer

Abemaciclib, previously known as LY2835219, is a potent and selective inhibitor of cyclin-dependent kinases: CDK4 and CDK6, developed by Eli Lilly, which is in clinical trial phase III for the treatment of breast cancer and non-small cell lung cancer...

(NSCLC) and in phase II for investigation of its treatment glioblastoma and melanoma.

CYCLOPENTYLAMINE

4259VRY3GN

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ACHIRAL)

ABEMACICLIB MESYLATE

KKT462Q807

Export Data
Search for Structure

Status:

US Approved Rx (2017)

First approved in 2017

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Cyclin-dependent kinase 6

Cyclin-dependent kinase 4

Conditions:

Non-small cell lung cancer

HER2-negative advanced breast cancer

Abemaciclib, previously known as LY2835219, is a potent and selective inhibitor of cyclin-dependent kinases: CDK4 and CDK6, developed by Eli Lilly, which is in clinical trial phase III for the treatment of breast cancer and non-small cell lung cancer...

(NSCLC) and in phase II for investigation of its treatment glioblastoma and melanoma.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1